פרדקסה 75
boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - קפסולות - dabigatran etexilate as mesilate 75 mg - dabigatran etexilate
זנטק סירופ
glaxo smith kline (israel) ltd - ranitidine as hydrochloride - סירופ - ranitidine as hydrochloride 150 mg / 10 ml - ranitidine - ranitidine - h2 receptor antagonist. for treatment of duodenal ulcer and benign gastric ulcer, including that associated with nsaid agents. post-operative ulcer, oesophageal reflux disease and zollinger-ellison syndrome. prophylaxis of stress ulceration in seriously ill patients. before general anaesthesia in patients considered to be of risk acid aspiration (mendelson's syndrome).
ספזמקס 30
tec-o-pharm-libra ltd - trospium chloride - טבליות מצופות פילם - trospium chloride 30 mg - trospium and analgesics - trospium and analgesics - for the treatment of vegetative bladder dysfunction accompanied by urgency and/or frequency and/or urinary incontinence.
רזין
cts chemical industries ltd, israel - phentermine as resinate - קפסולות - phentermine as resinate 15 mg - phentermine - phentermine - for the treatment of severe obesity that has not responded to an appropriate diet - a minimal body mass index of 30 kg/m2 is required.
קסניקל
tzamal bio-pharma ltd - orlistat - קפסולות - orlistat 120 mg - orlistat - orlistat - xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (bmi) greater or equal to 30 kg/m2, or overweight patients (bmi > 28 kg/m2) with associated risk factors.
קראון 10000
abbott medical laboratories ltd, israel - pancreatin - קפסולות - pancreatin 150 mg - multienzymes (lipase, protease etc.) - multienzymes (lipase, protease etc.) - pancreatic exocrine insufficiency.
קראון 25000
abbott medical laboratories ltd, israel - pancreatin - קפסולות - pancreatin 300 mg - multienzymes (lipase, protease etc.) - multienzymes (lipase, protease etc.) - for the treatment of pancreatic exocrine insufficiency.
רקורמון iu 5000
roche pharmaceuticals (israel) ltd - epoetin beta - תמיסה להזרקה - epoetin beta 5000 iu / 0.3 ml - erythropoietin - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative
רקורמון 10000 iu
roche pharmaceuticals (israel) ltd - epoetin beta - תמיסה להזרקה - epoetin beta 10000 iu / 0.6 ml - erythropoietin - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with chemotherapy. treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative erythropoietin deficiency* and are receiving anti-tumor therapy. * deficiency is defined as an
רקורמון 4000 iu
roche pharmaceuticals (israel) ltd - epoetin beta - תמיסה להזרקה - epoetin beta 4000 iu / 0.3 ml - erythropoietin - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative